We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT00401648
Previous Study | Return to List | Next Study

Effect of Brivaracetam in Photosensitive Epileptic Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00401648
Recruitment Status : Completed
First Posted : November 20, 2006
Last Update Posted : December 1, 2009
Information provided by:
UCB Pharma

Brief Summary:
to assess the effect of brivaracetam on the photoparoxysmal EEG response in photosensitive epileptic subjects

Condition or disease Intervention/treatment Phase
Epilepsy Drug: Brivaracetam Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 20 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: A Placebo-controlled, Single-blind, Multi-center Study to Explore the Photoparoxysmal Response in Photosensitive Epileptic Subjects After One Single Oral Dose of Brivaracetam in Capsules.
Study Start Date : September 2002
Actual Primary Completion Date : June 2003
Actual Study Completion Date : June 2003

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Epilepsy

Primary Outcome Measures :
  1. Identify lowest single oral dose producing maximal decrease or suppression of intermittent photic stimulation (IPS)photoparoxysmal response (PPR) in photosensitive epileptic subjects pre-dose
  2. post placebo during 24h and post brivaracetam for up to 72 h

Secondary Outcome Measures :
  1. Assess relationship between plasma concentrations and changes in photosensitivity frequency range, time of onset and duration of suppressing effect
  2. Safety

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • epileptic subjects with generalized PPR

Exclusion Criteria:

  • more than 2 concomitant antiepileptic drugs

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00401648

Layout table for location information
Marseille, France
Paris, France
Rouen, France
Strasbourg, France
Kork, Germany
Sponsors and Collaborators
UCB Pharma
Layout table for investigator information
Study Director: Philipp von Rosenstiel, MD. UCB Pharma
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00401648    
Other Study ID Numbers: N01069
Protocol Number RPCE02D2304
First Posted: November 20, 2006    Key Record Dates
Last Update Posted: December 1, 2009
Last Verified: November 2009
Keywords provided by UCB Pharma:
Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases